Determination of New Biomarkers of Septic Arthritis by Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight (SELDI-TOF) (NOUBASST)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT01010165
First received: November 6, 2009
Last updated: October 25, 2012
Last verified: December 2011

November 6, 2009
October 25, 2012
October 2009
October 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01010165 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Determination of New Biomarkers of Septic Arthritis by Surface-Enhanced Laser Desorption/Ionization Time-Of-Flight (SELDI-TOF)
Caractérisation de Nouveaux Biomarqueurs de l'Arthrite Septique Par Technique SELDI-TOF

Septic arthritis is a frequent, potentially disabling and/or life-threatening disease. To diagnose a septic arthritis is a complex procedure, first because of numerous differential diagnoses (such as crystal arthritis), second because of poor sensitivity of initial gram staining (for example after untimely antibiotic therapy).

This protocol will use SELDI-TOF as a tool to analyse joint fluid of patients with various acute, polymorphonuclear-rich arthritis, as to determine specific and sensitive new biomarkers of a septic origin.

Such biomarkers will allow rapid diagnosis of septic arthritis in the first hours of admission.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

joint fluid proteom

Non-Probability Sample

patients from the Grenoble University Hospital

Acute Arthritis
Not Provided
  • septic arthritis
  • crystal arthritis
  • rheumatismal disease
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
89
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • acute arthritis (onset not more than 7 days ago)
  • joint fluid leukocyte count : more than 2000/mm3, more than 50% polymorphonuclear

Exclusion Criteria:

  • none (apart from unability to accept inclusion)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01010165
0916, 2009-A00810-57
No
University Hospital, Grenoble
University Hospital, Grenoble
Not Provided
Principal Investigator: olivier epaulard, MD, PhD University Hospital, Grenoble
University Hospital, Grenoble
December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP